Trial Profile
Prospective study of ONCOS-102 and dendritic cell vaccine therapy in prostate cancer
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2017
Price :
$35
*
At a glance
- Drugs Dendritic cell vaccines (Primary) ; ONCOS 102 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors SOTIO
- 02 Nov 2017 According to a Targovax media release, the company is planning to recruit the first patient in this trial in H2 2017 and interim data expected in 2H 2018.
- 03 Dec 2015 New trial record